There are many exciting avenues to pursue in angiogenesis-related cancer research. Until now, conventional therapy has targeted neoplastic cells within a tumor. However, tumor vasculature is emerging as a new cancer target. Antiangiogenic drugs are unique in having highly specific targets, while simultaneously carrying the potential to be effective against a wide breadth of cancer types. They also act synergistically with cytotoxic therapy. Currently, this combination of new antiangiogenic treatments with traditional cytotoxic treatments such as radiotherapy, may provide a powerful means of combating cancer. Strategic combination therapy, selecting for tumor type and angiogenic profile, may result in the realization of the promise and potential of antiangiogenic therapy.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: